Arch Biopartners Inc (ARCH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arch Biopartners Inc (ARCH) has a cash flow conversion efficiency ratio of 0.072x as of March 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-465.38K ≈ $-336.65K USD) by net assets (CA$-6.44 Million ≈ $-4.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ARCH days of operational coverage to measure how many days the company can operate on defensive assets alone.
Arch Biopartners Inc - Cash Flow Conversion Efficiency Trend (1997–2023)
This chart illustrates how Arch Biopartners Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arch Biopartners Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arch Biopartners Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xos Inc
NASDAQ:XOS
|
0.099x |
|
Ropharma Bras
RO:RPH
|
0.057x |
|
Inuvo Inc
NYSE MKT:INUV
|
-0.152x |
|
Microelectronics Technology Inc
TW:2314
|
0.362x |
|
CodeMill AB
ST:CDMIL
|
0.052x |
|
Chonburi Concrete Product Public Company Limited
BK:CCP
|
0.074x |
|
Seyitler Kimya Sanayi AS
IS:SEYKM
|
0.049x |
|
Aspermont Ltd
AU:ASP
|
0.082x |
Annual Cash Flow Conversion Efficiency for Arch Biopartners Inc (1997–2023)
The table below shows the annual cash flow conversion efficiency of Arch Biopartners Inc from 1997 to 2023. For the full company profile with market capitalisation and key ratios, see Arch Biopartners Inc (ARCH) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-09-30 | CA$-5.51 Million ≈ $-3.99 Million |
CA$-234.07K ≈ $-169.33K |
0.042x | -82.41% |
| 2022-09-30 | CA$-4.47 Million ≈ $-3.23 Million |
CA$-1.08 Million ≈ $-781.28K |
0.242x | -68.53% |
| 2021-09-30 | CA$-3.88 Million ≈ $-2.81 Million |
CA$-2.98 Million ≈ $-2.16 Million |
0.768x | +55.91% |
| 2020-09-30 | CA$-3.87 Million ≈ $-2.80 Million |
CA$-1.90 Million ≈ $-1.38 Million |
0.492x | -20.82% |
| 2019-09-30 | CA$-2.90 Million ≈ $-2.10 Million |
CA$-1.80 Million ≈ $-1.31 Million |
0.622x | -79.66% |
| 2018-09-30 | CA$-1.05 Million ≈ $-756.50K |
CA$-3.20 Million ≈ $-2.31 Million |
3.058x | +126.66% |
| 2017-09-30 | CA$-563.41K ≈ $-407.56K |
CA$-760.17K ≈ $-549.89K |
1.349x | -52.55% |
| 2016-09-30 | CA$-256.91K ≈ $-185.85K |
CA$-730.53K ≈ $-528.45K |
2.843x | +184.73% |
| 2015-09-30 | CA$141.48K ≈ $102.34K |
CA$-474.82K ≈ $-343.47K |
-3.356x | -105.55% |
| 2014-09-30 | CA$-6.58K ≈ $-4.76K |
CA$-398.51K ≈ $-288.27K |
60.517x | +14513.69% |
| 2013-09-30 | CA$-425.37K ≈ $-307.70K |
CA$-176.15K ≈ $-127.42K |
0.414x | -49.91% |
| 2012-09-30 | CA$-355.42K ≈ $-257.10K |
CA$-293.82K ≈ $-212.55K |
0.827x | -51.89% |
| 2011-09-30 | CA$-174.98K ≈ $-126.58K |
CA$-300.68K ≈ $-217.51K |
1.718x | +237.73% |
| 2010-09-30 | CA$164.87K ≈ $119.26K |
CA$-205.71K ≈ $-148.81K |
-1.248x | -207.77% |
| 2009-09-30 | CA$-345.96K ≈ $-250.26K |
CA$-400.53K ≈ $-289.74K |
1.158x | +718.19% |
| 2008-09-30 | CA$-1.77 Million ≈ $-1.28 Million |
CA$-251.16K ≈ $-181.69K |
0.142x | -5.56% |
| 2007-09-30 | CA$-1.01 Million ≈ $-732.95K |
CA$-151.81K ≈ $-109.82K |
0.150x | +180.51% |
| 2006-09-30 | CA$-644.38K ≈ $-466.14K |
CA$119.92K ≈ $86.75K |
-0.186x | -135.10% |
| 2005-09-30 | CA$-887.26K ≈ $-641.83K |
CA$-470.38K ≈ $-340.27K |
0.530x | -64.76% |
| 2004-09-30 | CA$-639.29K ≈ $-462.45K |
CA$-961.78K ≈ $-695.74K |
1.504x | +139.16% |
| 2003-09-30 | CA$73.10K ≈ $52.88K |
CA$-280.87K ≈ $-203.17K |
-3.842x | +82.41% |
| 2002-09-30 | CA$17.10K ≈ $12.37K |
CA$-373.42K ≈ $-270.13K |
-21.841x | -1484.77% |
| 2001-09-30 | CA$-159.43K ≈ $-115.33K |
CA$-251.46K ≈ $-181.90K |
1.577x | +501.48% |
| 2000-09-30 | CA$2.05 Million ≈ $1.48 Million |
CA$-803.47K ≈ $-581.22K |
-0.393x | +50.09% |
| 1999-09-30 | CA$1.06 Million ≈ $766.49K |
CA$-834.06K ≈ $-603.34K |
-0.787x | -120.14% |
| 1998-09-30 | CA$-128.74K ≈ $-93.13K |
CA$-503.20K ≈ $-364.01K |
3.909x | -91.29% |
| 1997-09-30 | CA$-22.22K ≈ $-16.07K |
CA$-997.15K ≈ $-721.32K |
44.884x | -- |
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related … Read more